Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 24-Week Treatment Period and a 28-Week Extension

NCT07318688 is registered in ClinicalTrials.gov with Hope Medicine (Nanjing) Co., Ltd as lead sponsor.

NCT NCT07318688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07318688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 24-Week Treatment Period and a 28-Week Extension
Lead sponsor
Hope Medicine (Nanjing) Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
January 29, 2026
Completion date
September 1, 2028
Enrollment
540 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis